Jun 01, 2023
|
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE ® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million , an Increase of 17% YoY Forecasts FYCOMPA ® 2023 Net Product Revenue of Approximately $130 Million for 11 Months
|
May 30, 2023
|
CORAL GABLES, Fla. , May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today
|
May 10, 2023
|
Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms Full Year Total Revenue Guidance of Between $375 Million
|
May 09, 2023
|
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla. , May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
|
May 01, 2023
|
CORAL GABLES, Fla. , May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced
|
Apr 24, 2023
|
The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET CORAL GABLES, Fla. , April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
|
Apr 20, 2023
|
CORAL GABLES, Fla. , April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
|
Mar 15, 2023
|
Achieved Record 2022 Total Net Revenues of $214 Million , a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million , a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product
|
Mar 08, 2023
|
CORAL GABLES, Fla. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
|
Mar 01, 2023
|
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET CORAL GABLES, Fla. , March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
|